These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9167185)

  • 1. Ovarian cancer patients with high CA-125 but no symptoms--should antiangiogenic treatments be considered?
    Sharma A; Bernacki RJ
    Oncol Res; 1997; 9(2):53-4. PubMed ID: 9167185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA-125: an evolving role in the management of ovarian cancer.
    Markman M
    J Clin Oncol; 1996 May; 14(5):1411-2. PubMed ID: 8622053
    [No Abstract]   [Full Text] [Related]  

  • 5. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
    Markman M; Kennedy A; Kim J
    Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of CA 125 and TPS during treatment of ovarian cancer.
    Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Anticancer Res; 2000; 20(6D):5107-8. PubMed ID: 11326677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels.
    Fleming LW
    Scott Med J; 2001 Jun; 46(3):81-3. PubMed ID: 11501326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of CA-125 to assess response to new agents in ovarian cancer trials.
    Rustin GJ
    J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
    Markman M
    Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The evaluation of the efficacy of adjuvant laferon therapy in the combined treatment of patients with ovarian cancer based on the monitoring of the tumor marker Ca-125 in the blood serum].
    Zhyl'chuk VIe; Alistratov OV; Vorontsova AL
    Lik Sprava; 1998; (2):137-9. PubMed ID: 9670686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
    Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
    Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
    Rustin GJ; Nelstrop AE; McClean P; Brady MF; McGuire WP; Hoskins WJ; Mitchell H; Lambert HE
    J Clin Oncol; 1996 May; 14(5):1545-51. PubMed ID: 8622070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.